Navigation Links
Brain cell discovery could open doors to targeted cancer therapies
Date:4/11/2014

Fresh insights into the processes that control brain cell production could pave the way for treatments for brain cancer and other brain-related disorders.

Scientists have gained new understanding of the role played by a key molecule that controls how and when nerve and brain cells are formed a process that allows the brain to develop and keeps it healthy. Their findings could help explain what happens when cell production goes out of control, which is a fundamental characteristic of many diseases including cancer.

Researchers have focused on a RNA molecule, known as miR-9, which is linked to the development of brain cells, known as neurons and glial cells. They have shown that a protein called Lin28a regulates the production of miR-9, which in turn controls the genes involved in brain cell development and function.

Scientists carried out lab studies of embryonic cells, which can develop into neurons, to determine how Lin28a controls the amount of miR-9 that is produced.

They found that in embryonic cells, Lin28a prevents production of miR-9 by triggering the degradation of its precursor molecule. In developed brain cells, Lin28a is no longer produced, which enables miR-9 to accumulate and function. In cancer cells, Lin28a production is re-established, and as a result this natural process is disrupted.

Researchers used a series of lab tests to unravel the complex processes that are directed by the Lin28a protein. They say further studies could help explain fully the role of Lin28a and miR-9 in brain development, and pave the way to the development of novel therapies.

Dr Gracjan Michlewski of the School of Biological Sciences, who led the study, said: "Understanding more of the complex science behind the fundamental processes of cell development will helps us learn more about what happens when this goes wrong and what might be done to prevent it."


'/>"/>

Contact: Catriona Kelly
Catriona.Kelly@ed.ac.uk
44-131-651-4401
University of Edinburgh
Source:Eurekalert

Page: 1

Related medicine news :

1. Deep, integrated genomic analysis re-classifies lower-grade brain tumors
2. UCSF launches groundbreaking online registry to drive brain disease research
3. DNA modifications measured in blood signal related changes in the brain
4. Lipid levels during prenatal brain development impact autism: York U study
5. Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders
6. Using your loaf to fight brain disease
7. Anesthetic technique important to prevent damage to brain
8. Adult cancer drugs show promise against an aggressive childhood brain tumor
9. The Brain & Behavior Research Foundation awards $4 million in NARSAD Grants
10. USF study finds stem cell combination therapy improves traumatic brain injury outcomes
11. US headache sufferers get $1 billion worth of brain scans each year, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Source Vitál Apothecary, a skin and body care company dedicated ... company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition ... in the nutritional, sports and health industries a chance to meet in private sessions ...
(Date:1/20/2017)... ... 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to ... a successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports ... to provide its products to all clients at reasonable prices. At the ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Michael and Betsy ... Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as she ... not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The ... 233.7 billion by 2025, according to a new ... is anticipated to be predominantly driven by high ... into the large-scale production of new and therapeutically ... influx of drugs at an unprecedented rate into ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda ... will release results for the fourth quarter of 2016 on Wednesday, ... ... at 4:30 PM ET on Wednesday, February 15, 2017, during which ... results and other corporate activities. To participate in the conference call, ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: